<DOC>
	<DOCNO>NCT01860989</DOCNO>
	<brief_summary>This study ass efficacy , safety , tolerability PK uncomplicated adult malaria patient acute P. falciparum infection single dose KAE609 75 mg , 150mg , 225mg 300mg/day</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety KAE609 Adult Patients With Acute Malaria Mono-infection</brief_title>
	<detailed_description>study comprise 4 sequential cohort , total 48 patient enrol study . cohort 1 : 6-12 patient receive 75mg single dose . cohort 2 : 6-12 patient receive 150mg single dose . cohort 3 : 6-12 patient receive 225mg single dose . cohort 4 : 6-12 patient receive 300mg single dose . After approximately every 6 patient cohort treat give dose complete first 15 day , safety tolerability data review conduct Data Monitoring Committee ( DMC ) . Consensus agreement DMC require either escalate next dose level expand give cohort additional 6 patient order obtain safety data .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Male female patient age 20 60 year Presence monoinfection P. falciparum Weight 40 kg 90 kg Patients sign symptom severe/complicated malaria Mixed Plasmodium infection Presence serious chronic clinical condition require hospitalization . Severe malnutrition Significant chronic medical condition opinion investigator preclude enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>parasitemia</keyword>
</DOC>